T Cell Receptor-Vβ Analysis Identifies a Dominant CD60+ CD26– CD49d– T Cell Clone in the Peripheral Blood of Sézary Syndrome Patients-Reference-Cited by-同舟云学术

T Cell Receptor-Vβ Analysis Identifies a Dominant CD60+ CD26– CD49d– T Cell Clone in the Peripheral Blood of Sézary Syndrome Patients

Published:2002-07 Issue:1 Volume:119 Page:193-196
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Scala Enrico,Narducci Maria Grazia,Amerio Paolo,Baliva Giannandrea,Simoni Romeo,Silvestri Lorena,Puddu Pietro,De Pita Ornella,Russo Giandomenico,Giovannetti Antonello

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference14 articles.

1. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma;Bagot;Blood,1998

2. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells;Bernengo;Br J Dermatol,2001

3. Failure of anti-T-cell receptor V beta antibodies to consistently identify a malignant T-cell clone in Sézary syndrome;Bigler;Am J Pathol,1996

4. Genotypic, phenotypic and functional analysis of CD4+CD7+ and CD4+CD7- T lymphocyte subsets in Sézary syndrome;Dummer;Arch Dermatol Res,1999

5. Protein displays of the human T cell receptor alpha, beta, gamma and delta variable and joining regions;Folch;Exp Clin Immunogenet,2000

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis;Journal of Investigative Dermatology;2022-11

2. CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome;Blood Advances;2021-09-27

3. Pleomorphicskin eruptions in a COVID‐19 affected patient: Case report and review of the literature;Immunity, Inflammation and Disease;2021-05-04

4. References;Flow Cytometry of Hematological Malignancies;2021-04-06

5. Sézary Syndrome, recent biomarkers and new drugs;Chinese Clinical Oncology;2019-02